
- Oncology NEWS International Vol 18 No 6
- Volume 18
- Issue 6
ADT in prostate ca increases risk of bone and heart complications
Prostate cancer patients who undergo androgen deprivation therapy have an increased chance of developing bone- and heart-related side effects compared to patients who do not undergo ADT, according to an analysis in Cancer online (April 29, 2009).
Prostate cancer patients who undergo androgen deprivation therapy have an increased chance of developing bone- and heart-related side effects compared to patients who do not undergo ADT, according to an analysis in Cancer online (April 29, 2009).
Researchers from the University of Texas Health Sciences Center in Houston found that men treated with ADT had an increased risk of bone fractures and heart-related death, although the absolute risk for both was still low.
For bone fractures, there was a 23% increased risk compared to prostate cancer patients who did not undergo ADT.
The absolute risk of fracture among ADT-exposed men was 7.2 per 100 person years.
For heart-related death, the increased risk among ADT-exposed men was 17% higher compared to other prostate cancer patients. However, because the baseline risk is low, the increase translated to an additional one-to-two deaths per 1,000 men who received ADT. Lead author Lockwood G. Taylor, MPH, and colleagues also noted a link between ADT and diabetes.
Articles in this issue
over 16 years ago
Abraxis backs SPARC as prognostic biomarkerover 16 years ago
ALK-1 receptor: New target in angiogenesisover 16 years ago
Abraxane prolongs PFS in metastatic diseaseover 16 years ago
SAVI applicator removes obstacles associated with brachytherapyover 16 years ago
Mistrust, costs reduce breast cancer screening among minoritiesover 16 years ago
Oral chemotherapy poses more challenges for cancer communityover 16 years ago
CMS nixes CT colonography screeningover 16 years ago
New ultrasound strategy helps pinpoint prostate tumorsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.